Clinical Trials Browser

Congenital Abnormalities, Carcinoma, Ovarian Epithelial, Blast Crisis, Breast Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Leukemia, Hairy Cell, Leukemia, Mast-Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Ovarian Neoplasms, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Breast Neoplasms, Male, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Intraocular Lymphoma

NCT00116961 2012-02-07

Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma

Phase 2 Completed

40 enrolled

Plasma cell

Multiple Myeloma

NCT00135187 2012-02-07

Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma

Phase NA Completed

30 enrolled

Plasma cell

Multiple Myeloma

NCT00344422 2011-06-10

Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Completed

198 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Clinical Trials

Doxil/Caelyx BE Study

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma

A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life

RVDD

A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma

Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma

Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)

Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma

Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma

Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma